Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here?

(2013) William J. Sandborn   DIGESTIVE DISEASES

Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement

(2013) Eric Toussirot et al.   Patient Preference and Adherence

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing Response and Loss of Response to Biological Therapies in IBD

(2011) Henit Yanai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases

(2011) Warren Strober et al.   GASTROENTEROLOGY

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Review of the safety and efficacy of ustekinumab

(2010) Ellen J. Scherl et al.   Therapeutic Advances in Gastroenterology

Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease

(2009) Kai Wang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET